Biotronik Archives - Cardiovascular News

Teleflex completes acquisition of Biotronik’s Vascular Intervention business

2nd July 2025

Teleflex today announced ...

Trial of DCB and scaffold technologies enrols first CTO-PCI patients

5th June 2025

Biotronik has announced t...

Teleflex announce acquisition of Biotronik’s Vascular Intervention business

27th February 2025

Teleflex has today announ...

BIOMAG-I two year results confirm safety and efficacy of Biotronik resorbable magnesium scaffold

20th May 2024

New two-year follow-u...

First patient enrolled in BIOMAG-II trial of Freesolve resorbable scaffold

13th May 2024

Biotronik has announced t...

Biotronik’s Freesolve resorbable magnesium scaffold gains CE mark

13th February 2024

Biotronik has announced t...

Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro

6th May 2020

According to recently...

Orsiro Mission gets CE mark

12th February 2020

Biotronik has receive...

Biotronik appoint company’s first chief medical officer

28th January 2020

David Hayes, former p...

ESC 2019: Ultrathin strut Orsiro better than thin strut Xience for STEMI patients

2nd September 2019

One-year data from th...

Biotronik announces positive data for Magmaris

11th June 2019

A press release from ...

Biotronik launches PK Papyrus covered coronary stent in the USA

30th April 2019

Biotronik has launche...

CRT 2019: Early resorption and low complications demonstrated for Magmaris

7th March 2019

A press release repor...

CRT 2019: Three-year data shows trend towards lower target vessel failure with Orsiro vs. Resolute Integrity and Synergy

7th March 2019

Three-year outcome da...

New Australian research and development partnership aims to innovate heart failure care

1st March 2019

Biotronik, the University...

FDA approves Orsiro for use in the USA

25th February 2019

The US FDA ...

Registry data for Biotronik’s bioresorbable scaffold Magmaris supports its roll-out into clinical practice

1st February 2019

Preliminary data from...

TCT 2018: Orsiro continues to have lower rates of target lesion failure than Xience

27th September 2018

Two-year data from th...

US FDA approves PK Papyrus stent for coronary perforations

17th September 2018

The US FDA has approv...

ESC 2018: Higher all-cause mortality with Orsiro at five years than with Xience

31st August 2018

According to the five...

EuroPCR 2018: One- to two-year landmark analysis shows significantly lower target lesion failure with Orsiro vs. Resolute Integrity

31st May 2018

Two-year outcome data...

EuroPCR 2018: Further evidence for safety and efficacy of Magmaris bioresorbable scaffold

23rd May 2018

Data presented during...

CIT 2018: BIOFLOW-VI confirms non-inferiority of Orsiro to Xience

29th March 2018

Nine and 12-month dat...

Japanese Ministry of Health approve Biotronik’s Orsiro drug-eluting stent

22nd January 2018

According to a Biotro...

TCT 2017: Pooled analysis of Magmaris studies continue to show no instances of scaffold thrombosis at 12 months

8th November 2017

Data presented during...

Enrolment in BIOVITESSE trial of polymer-free coronary stent initiated

11th October 2017

Biotronik has announced t...

ESC 2017: Significantly lower event rates with Orsiro than with Xience

1st September 2017

Results fro...

EuroPCR 2017: Low risk of scaffold thrombosis with Magmaris

22nd May 2017

Data presented at Eur...

Magnesium 1,000 programme reveals high deployment success for Biotronik’s Magmaris scaffold

30th March 2017

Biotronik has release...

BIOFLOW-IV confirms non-inferiority of Biotronik’s Orsiro in Japan

21st March 2017

The 12-month results ...

FDA approves Biotronik’s Pro-Kinetic Energy bare metal stent

15th February 2017

Biotronik’s Pro-Kinet...

TCT 2016: Physicians discuss their positive experiences of using a metallic scaffold

1st November 2016

At a symposium at the...

Tag: Biotronik